
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The multistate outbreak of vaping-related lung injury is ongoing, but the CDC's updated interim guidance can help physicians navigate the clinical evaluation and management of these patients.






